INTEGRATED BIOPHARMA INC (INBP) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
225 LONG AVENUE HILLSIDE, NJ 07205 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2025 MRQ | 12/31/2024 MRQ | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 2,461 | 1,677 | 1,316 | 331 | 210 | 402 | |||
| Cash and cash equivalent | 2,461 | 1,677 | 1,316 | 331 | 210 | 402 | |||
| Receivables | 4,228 | 4,668 | 4,511 | 4,888 | 5,776 | 5,507 | |||
| Inventory, net of allowances, customer advances and progress billings | 11,066 | 11,244 | 10,261 | 11,055 | 11,695 | 10,101 | |||
| Inventory | 11,066 | 11,244 | 10,261 | 11,055 | 11,695 | 10,101 | |||
| Other current assets | 398 | 286 | 284 | 352 | 317 | 451 | |||
| Total current assets: | 18,153 | 17,875 | 16,372 | 16,626 | 17,998 | 16,461 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | |||||||||
| Operating lease, right-of-use asset | 1,323 | 1,790 | 2,623 | 1,867 | 2,365 | 2,824 | |||
| Property, plant and equipment | 1,771 | 1,885 | 1,653 | 1,910 | 1,742 | 1,696 | |||
| Deposits noncurrent assets | 61 | 56 | 57 | 49 | 67 | 80 | |||
| Deferred income tax assets | 4,353 | 4,601 | 4,726 | 4,798 | 3,268 | 1,883 | |||
| Total noncurrent assets: | 7,508 | 8,332 | 9,059 | 8,624 | 7,442 | 6,483 | |||
| TOTAL ASSETS: | 25,661 | 26,207 | 25,431 | 25,250 | 25,440 | 22,944 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,808 | 2,510 | 2,266 | 3,209 | 3,496 | 4,358 | |||
| Accounts payable | 2,808 | 2,510 | 2,266 | 3,209 | 3,496 | 4,358 | |||
| Debt | 7 | 42 | 32 | 1,457 | 2,823 | ||||
| Other undisclosed current liabilities | 2,767 | 3,606 | 2,520 | 2,022 | 4,283 | 5,918 | |||
| Total current liabilities: | 5,575 | 6,123 | 4,828 | 5,263 | 9,236 | 13,099 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 7 | 1,412 | 1,870 | 3,778 | |||||
| Long-term debt, excluding current maturities | 7 | 53 | 1,436 | ||||||
| Finance lease, liability | |||||||||
| Liabilities, other than long-term debt | 359 | 846 | 1,735 | ||||||
| Operating lease, liability | 359 | 846 | 1,735 | 1,359 | 1,870 | 2,342 | |||
| Other undisclosed noncurrent liabilities | (1,359) | (1,870) | (2,342) | ||||||
| Total noncurrent liabilities: | 359 | 846 | 1,742 | 1,412 | 1,870 | 3,778 | |||
| Total liabilities: | 5,934 | 6,969 | 6,570 | 6,675 | 11,106 | 16,877 | |||
| Equity | |||||||||
| Equity, attributable to parent | 19,727 | 19,238 | 18,861 | 18,575 | 14,334 | 6,067 | |||
| Common stock | 61 | 60 | 60 | 60 | 60 | 59 | |||
| Treasury stock, value | (99) | (99) | (99) | (99) | (99) | (99) | |||
| Additional paid in capital | 51,617 | 51,504 | 51,239 | 50,919 | 50,516 | 50,263 | |||
| Accumulated deficit | (31,852) | (32,227) | (32,339) | (32,305) | (36,143) | (44,156) | |||
| Total equity: | 19,727 | 19,238 | 18,861 | 18,575 | 14,334 | 6,067 | |||
| TOTAL LIABILITIES AND EQUITY: | 25,661 | 26,207 | 25,431 | 25,250 | 25,440 | 22,944 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 52,124 | 50,317 | 50,672 | 56,246 | 63,559 | 52,769 | ||
| Cost of revenue (Cost of Product and Service Sold) | (47,050) | (46,433) | (46,611) | (49,694) | (54,079) | (46,042) | ||
| Gross profit: | 5,074 | 3,884 | 4,061 | 6,552 | 9,480 | 6,727 | ||
| Operating expenses | (3,625) | (3,633) | (3,941) | (3,807) | (3,696) | (3,468) | ||
| Operating income: | 1,449 | 251 | 120 | 2,745 | 5,784 | 3,259 | ||
| Nonoperating income (expense) | (8) | 17 | (20) | (148) | 1,463 | (171) | ||
| Other nonoperating income (expense) | (27) | (1) | 40 | 35 | 57 | 51 | ||
| Interest and debt expense | 25 | (52) | (52) | (128) | 1,639 | (397) | ||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 18 | (1,639) | 397 | |||||
| Income from continuing operations before equity method investments, income taxes: | 1,484 | 216 | 48 | 2,469 | 7,247 | 3,088 | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (29) | 52 | 52 | 128 | ||||
| Income from continuing operations before income taxes: | 1,455 | 268 | 100 | 2,597 | 7,247 | 3,088 | ||
| Income tax expense (benefit) | (527) | (156) | (134) | 1,241 | 766 | 1,020 | ||
| Income (loss) from continuing operations: | 928 | 112 | (34) | 3,838 | 8,013 | 4,108 | ||
| Income before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | 3,838 | 8,013 | 4,108 | |
| Net income (loss) available to common stockholders, diluted: | 928 | 112 | (34) | 3,838 | 8,013 | 4,108 | ||
Comprehensive Income ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 928 | 112 | (34) | 3,838 | 8,013 | 4,108 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 928 | 112 | (34) | 3,838 | 8,013 | 4,108 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.